Robert Clarke (Kinaset)
Kinaset launches with $40M and a JAK inhibitor from Vectura's old pipeline
Kinaset Therapeutics is joining the search for a better severe asthma treatment, picking up where Vectura left off when it decided to clear house last …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.